Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Illumina® Protein Prep launches to drive greater proteomic insights for improved…
Launch follows Illumina's announcement of agreement to acquire SomaLogic Launch follows Illumina's announcement of agreement to acquire SomaLogic SAN DIEGO , Sept. 3, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of Illumina Protein Prep, an assay introducing superior performance for next-generation sequencing (NGS) based proteomics discovery at scale.Illumina Protein Prep has been available through an early-access program, and is now broadly...
PR Newswire
03/09/2025
Persephoni Launches Strategic Sponsorship with American Cancer Society’s…
RESEARCH TRIANGLE PARK, N.C., Sept.03, 2025(GLOBE NEWSWIRE) -- Persephoni BioSciences LLC ("Persephoni"), a leading global life sciences venture studio, is proud to announce a $1.5 million sponsorship to American Cancer Society BrightEdge LLC ("BrightEdge") in support of its innovation acceleration programs. As a leading sponsor, Persephoni and BrightEdge will also develop a strategic partnership with the mission to accelerate translational oncology research into…
Nasdaq GlobeNewswire
03/09/2025
Zero Candida Technologies Reports Financial Results for Three and Six Months…
"Q2 has been an important quarter for advancing our device toward human use and laying the foundation for our regulatory and clinical strategy," said Eli Ben-Haroosh, Chairman & CEO of Zero Candida Technologies. "Our discussions with leading hospitals and U.S. pharmaceutical companies this past quarter reinforce both the clinical need and commercial potential of our technology. With regulators and policymakers calling for safer, less drug-reliant healthcare therapies that…
PR Newswire
03/09/2025
AliveDx announces U.S. Food and Drug Administration (FDA) 510(k) submission for…
The MosaiQ AiPlex® VAS multiplex assay, is designed to advance the testing of anti-MPO, anti-PR-3 and anti-GBM for Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides and Anti-GBM (Goodpasture's) disease and improve time to results to support diagnosis of autoimmune vasculitis. The assay is intended to be used on the recent FDA listed Class II 510(k) exempt approved MosaiQ instrument. The equivalent assay has been commercially available in IVDR CE-marking countries since July…
PR Newswire
03/09/2025
Brainomix Stroke AI Software Hailed as ῾Revolutionary,' Helping More Patients…
Brainomix 360 Stroke is a comprehensive platform powered by highly advanced AI algorithms, supporting clinicians by providing real-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients in both specialist and general hospitals. Brainomix 360 Stroke is a comprehensive platform powered by highly advanced AI algorithms, supporting clinicians by providing real-time interpretation of brain scans to help guide treatment and transfer decisions for…
PR Newswire
03/09/2025
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating…
Media ReleaseCOPENHAGEN, Denmark; September 3, 2025 Trial demonstrated the feasibility of treating and monitoring adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in an outpatient setting Results showed that 92% of patients with R/R DLBCL received the first full dose of epcoritamab monotherapy in an outpatient settingAdverse event profile and efficacy were consistent with previously reported studies in R/R DLBCL patients Data also demonstrated 64...
Nasdaq GlobeNewswire
03/09/2025
SPS Expands Philips SpeechLive with Ambient Medical AI Documentation, Powered by…
Dr. Thomas Brauner, CEO of SPS said of the partnership: "Philips SpeechLive has always set the gold standard in our industry. By adding Corti's API directly into our platform, we're giving our customers the latest capabilities without forcing them to learn new systems or abandon familiar workflows. Together, we are redefining how speech empowers healthcare professionals worldwide to free up time for what matters most - the patient." Dr.Thomas Brauner, CEO of SPSsaid of the…
PR Newswire
03/09/2025
THE HOUSE OF HARRY WINSTON OPENS A NEW FLAGSHIP SALON IN GINZA
"Japan holds a special place in the history of Harry Winston. Since opening our first salon in 1988, Japan has played an integral role in building the House's renowned global legacy," said Nayla Hayek, CEO of Harry Winston, Inc. "Set in Ginza – the epicenter of luxury, where forward thinking design meets enduring tradition – the opening of our new Flagship represents an exciting new chapter – one that honors the House's longstanding relationship in Tokyo, while also offering a…
PR Newswire
03/09/2025
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation…
Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level);No cases of amyloid-related imaging abnormalities (ARIA) observed to date;The trial, expected to enroll 128 patients, remains on track to report 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026.Cambridge, Massachusetts, Sept.03, 2025(GLOBE NEWSWIRE) --ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing...
Nasdaq GlobeNewswire
03/09/2025
THE HOUSE OF HARRY WINSTON OPENS A NEW FLAGSHIP SALON IN GINZA
"Japan holds a special place in the history of Harry Winston. Since opening our first salon in 1988, Japan has played an integral role in building the House's renowned global legacy," said Nayla Hayek, CEO of Harry Winston, Inc. "Set in Ginza – the epicenter of luxury, where forward thinking design meets enduring tradition – the opening of our new Flagship represents an exciting new chapter – one that honors the House's longstanding relationship in Tokyo, while also offering a…
PR Newswire
03/09/2025
Diabetic Foot Ulcers Market Size to Reach USD 9.25 Billion with 6.1% CAGR by…
North America leads in DFU treatment adoption, supported by a high diabetic population, robust healthcare infrastructure, and increasing product launches. Meanwhile, the Asia Pacific is emerging as the fastest-growing region, driven by a rising diabetic population, healthcare investments, and expanding access to specialized wound care. With the aging global population and increasing focus on limb preservation and quality of life, diabetic foot ulcer management is becoming a critical priority in…
PR Newswire
03/09/2025
Biotechnology Market is Estimated to Reach USD 6.64 Trillion by 2032 | SkyQuest…
Get a Free Sample Report - https://www.skyquestt.com/sample-request/biotechnology-market Get a Free Sample Report -https://www.skyquestt.com/sample-request/biotechnology-market Biotechnology Market Dynamics Surge in incidence of chronic and genetic diseases, including cancer, cardiovascular disorders, and autoimmune conditions is primarily boosting the demand for cell therapies. These therapies offer promising curative potential, especially for patients unresponsive to conventional...
PR Newswire
03/09/2025
ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT AUGUST 2025
Accumulated revenue for January – August 2025 increased by 55 % to SEK 2,028.7 (1,309.9) million. Accumulated revenue for January –August 2025increased by 55 % toSEK 2,028.7(1,309.9) million. Revenues were distributed as follows: Countries in regions: -The Nordics:Denmark, Faroe Island,Finland,Iceland,Norway,Sweden - Central Europe :Austria,Germany,Switzerland - East Europe :Czech Republic,Slovakia,Hungary,Poland,Romania -South...
PR Newswire
03/09/2025
Surgical Robots Market to Grow at a CAGR of 13.4% from 2025 to 2032 | SkyQuest…
Get a Free Sample Report - https://www.skyquestt.com/sample-request/surgical-robots-market Get a Free Sample Report -https://www.skyquestt.com/sample-request/surgical-robots-market Surgical Robots Market Dynamics: Some of the main drivers of the surgical robots market is the growing preference of minimally invasive surgeries to both patients and surgeons due to their decreased length of recovery, lower risk of complications, and shorter length of time spent in the hospital...
PR Newswire
03/09/2025
Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD…
Dr Amir Hefni, Chief Executive Officer of Resolution Therapeutics, said: "The first patient dosed represents a significant milestone in advancing RTX001 as a potential first-in-class treatment option for patients with end-stage liver disease, a condition with high mortality and severely limited therapeutic options. We look forward to reporting our first clinical readouts from the EMERALD study in 2026." DrAmir Hefni, Chief Executive Officer of Resolution Therapeutics, said: "The…
PR Newswire
03/09/2025
Terumo Neuro Launches Aneurysm Treatment Alliance in EMEA to Advance Physician…
The Aneurysm Treatment Alliance is a new EMEA initiative created to strengthen engagement with physicians, streamline collaboration, and highlight Terumo Neuro's differentiated hemorrhagic portfolio for aneurysm treatment. By providing standardized tools and a collaborative platform, the Alliance supports physicians in advancing patient care across the region. The Aneurysm Treatment Alliance is a new EMEA initiative created to strengthen engagement with physicians, streamline collaboration…
PR Newswire
03/09/2025
LenioBio partners with AffinityAI to accelerate discovery of novel complex…
"We have reinvented cell-free protein expression to fully harness the power of AI-driven protein design", said André Goerke, CEO of LenioBio. "ALiCE® combines the openness and flexibility of a cell-free system with the scalability of cell-based platforms. Together with AffinityAI, we can accelerate discovery cycles and bring precision-designed protein therapeutics to development much faster." " We have reinvented cell-free protein expression to fully harness the power of…
PR Newswire
03/09/2025
ViCentra Raises $85M to Scale Manufacturing and Accelerate Market Penetration of…
"Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honors those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve," said Tom Arnold, Chief…
PR Newswire
03/09/2025
Terumo Neuro Unveils New SOFIA™ Flow 88 Neurovascular Aspiration Catheter Data…
Collected from 70 procedures across 16 EMEA Hospitals and 31 physicians, the preference test revealed: Collected from70 procedures across 16 EMEA Hospitals and 31 physicians, the preference test revealed: "TheSOFIAFlow 88 Neurovascular Aspiration Catheter represents a meaningful advancement in mechanical thrombectomy therapy across EMEA," saidCarsten Schroeder, President and CEO of Terumo Neuro. "Its super bore design maximizes aspiration and minimizes flow disruption while...
PR Newswire
03/09/2025
Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment…
Leiden, the Netherlands, September 3, 2025:Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the H.C. Wainwright 27 thAnnual Global Investment Conference in New York on September 8-10, 2025.Fabrice Chouraqui, Chief Executive Officer, will present on Monday, September 8 at 1:30pm EDT/19:30 CEST. A live webcast and replay of the presentation can be found in the “Upcoming Events” and “News” sections of...
Nasdaq GlobeNewswire
03/09/2025
Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for…
Strong immune response after third yearly booster dose in children and adultsSignificant anamnestic antibody response across all six serotypesNo safety concerns observed in any age group by independent Data Monitoring Committee (DMC), consistent with previous booster results.Saint-Herblain (France), September 3 rd, 2025– Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced positive immunogenicity and safety data from the ongoing Phase 2 study of Lyme disease...
Nasdaq GlobeNewswire
03/09/2025
NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as…
NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as Chief Medical Officer Seasoned clinical development leader brings deep expertise in neuromuscular disease research, drug development, and commercialization in the US and EuropeWill spearhead the continued advancement of NMD670 through three ongoing Phase 2 clinical trials, ensuring Phase 3 readiness Aarhus, Denmark, 3 September 2025– NMD Pharma A/S, a clinical-stage biotech company dedicated to...
Nasdaq GlobeNewswire
03/09/2025
EQ Europe: Culture, Not Capital, Kills Mergers
STOCKHOLM, Sept. 3, 2025 /PRNewswire/ -- In 2024, hundreds of mergers and acquisition transactions were conducted in Sweden to a value of over 150 million SEK. It is well known that over 70% of investments fail to meet their objectives. At least 30% of these failed transactions are caused directly by cultural integration issues such as unsynchronised leadership and culture clashes. (McKinsey, Deloitte, KPMG). The due diligence process simply isn't good enough at minimizing human risks. ...
PR Newswire
03/09/2025
Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a…
Alzheimer's disease is a progressive, deadly disease with amyloid beta (Aβ) and tau as hallmarks that is caused by a continuous underlying neurotoxic process that begins before amyloid plaque removal and continues afterward.1,2,3 Only Leqembi fights Alzheimer's disease in two ways – targeting both amyloid plaque and protofibrilsi, which can impact tau downstream. Alzheimer's disease is a progressive, deadly disease with amyloid beta (Aβ) and tau as hallmarks that is caused by a continuous...
PR Newswire
03/09/2025
Altri Comunicati
